Amarin (AMRN) 2020 Spend Guidance Significantly Above Street, Maintains Underperform - Oppenheimer

Go back to Amarin (AMRN) 2020 Spend Guidance Significantly Above Street, Maintains Underperform - Oppenheimer

Amarin Corporation (AMRN) Expenses May Drive Expenses Higher but Vascepa Peak Sales Remains the Key for Investors - Cantor Fitzgerald

January 7, 2020 7:42 AM EST

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35.00 price target on Amarin Corporation (NASDAQ: AMRN) after the company provided a business update, including an update of preliminary 2019 results and guidancethat was mostly in-line with the guidance given on 12/13. The company did however... More

Amarin Corp. (AMRN) Reports Prelim. FY19 Revenue Expected to be Slightly Above Upper End of Guidance; FY20 Revenue Views Unchanged

January 7, 2020 6:07 AM EST

Amarin Corporation plc (NASDAQ: AMRN), today provided a business update, including an update of preliminary 2019 results and additional 2020 financial guidance. Amarin plans to discuss these results and expectations with investors in connection with the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, at which Amarin is scheduled to present on Wednesday, January 15, 2020, at 10:30 a.m. Pacific Time (PT) / 1:30 p.m. Eastern Time (ET).

Preliminary (unaudited) 2019 Financial Results

Record Revenue Levels: 2019 net total revenue, subject to audit,... More